Cara Therapeutics, Inc. (CARA)

Market Cap	38.27M
Revenue (ttm)	20.97M
Net Income (ttm)	-118.51M
Shares Out	54.67M
EPS (ttm)	-2.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	306,841
Open	0.717
Previous Close	0.672
Day's Range	0.640 - 0.717
52-Week Range	0.500 - 4.670
Beta	0.70
Analysts	Strong Buy
Price Target	9.79 (+1,298.57%)
Earnings Date	May 13, 2024

About CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruish...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2014
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: CARA

Financial Performance

In 2023, CARA's revenue was $20.97 million, a decrease of -49.92% compared to the previous year's $41.87 million. Losses were -$118.51 million, 38.7% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for CARA stock is "Strong Buy." The 12-month stock price forecast is $9.79, which is an increase of 1,298.57% from the latest price.

Price Target

$9.79

(1,298.57% upside)

Analyst Consensus: Strong Buy